Clinical trial · Interventional
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
NCT00083434CI-TRIAL-00004738terminatedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This study was stopped because of an inadequate rate of enrollment.
Summary
Brief summary (as posted)
The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epoetin alfa | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older * Body weight \>/= 99lbs * ECOG 0-2 * Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy * Screening hemoglobin level of \</= 11.0 g/dL for men or \</= 10.0 for women Exclusion Criteria: * History of or concurrent second malignancy * Evidence of primary or metastatic malignancy involving the Central Nervous System
References
Publications (0)
Data not yet available
No reference posted for this study.